PGEN · Precigen, Inc.
Key customers — 49.9% of revenue (the three months ended March 31, 2025)
“For the three months ended March 31, 2025, four customers accounted for 49.9% of total condensed consolidated revenues.”
Price & Indicators
Up next
Metrics snapshot
Useful current figures from the complete screener profile.
AI Brief
Q2 FY26 earnings call · Aug 4, 2026TL;DR. Precigen reported Q2 PAPZIMEOS revenue of $53.1 million (up from $21.6 million in Q1) and achieved quarterly net income of $20.1 million, and reiterated its existing guidance that current cash plus receivables will fund operations through cash flow break-even by end of 2026.
- + FDA granted seven-year market exclusivity for PAPZIMEOS in adult RRP, extending into August 2032
- + Durability data strengthened with 83% of patients in ongoing complete response beyond three years and some beyond four years surgery-free
- − Other expense, net worsened by $7.7 million year-over-year due to new $3.0 million interest expense on long-term debt
AI-generated from the earnings call and 8-K · may contain errors · not investment advice
Equibles Rating
blended score · not investment adviceBlended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.
Guidance & track record
Guidance from company 8-Ks · delivered figures from as-reported statements · no analyst estimates involved.
Technicals
trend & momentum for long-term holders BuyIllustrative technical + ownership context — a signal mix, not investment advice.
Key metrics
the company's own KPIs, from written earnings releases and filings| Metric | Latest | Period | YoY |
|---|---|---|---|
| AdenoVerse immunotherapy platform (external development expense) | $1.57M | the three months ended June 30, 2026 filing | -58.3% |
|
|
|||
| Cash, cash equivalents, and investments | $38.7M | as of June 30, 2026 | — |
| PAPZIMEOS net revenue | $53.1M | the second quarter of 2026 | — |
|
|
|||
| Payer coverage US lives | 315M | as of the second quarter of 2026 | — |
| UltraCAR-T therapeutics platform (external development expense) | $123K | the three months ended June 30, 2026 filing | -69.3% |
|
|
|||
Figures exactly as the company stated them in writing · click a metric with a to chart its history · period links open the stating document · "filing" marks figures stated in the 10-K/10-Q · YoY needs an exactly comparable prior-year period
Versus peers
Biotechnology — same industry group| Company | Mkt cap | YTD | Rev growth Y/Y | P/E | Short % shares |
|---|---|---|---|---|---|
|
PGEN
this stock
Precigen, Inc.
|
$2.80B | +86.8% | +21.0% | — | 13.3% |
|
VRTX
Vertex Pharmaceuticals Inc / Ma
|
$129.29B | +12.5% | +46.2% | 29.7 | 1.8% |
|
MRNA
Moderna, Inc.
|
$89.83B | +663.0% | +4.3% | — | 7.7% |
|
REGN
Regeneron Pharmaceuticals, Inc.
|
$76.86B | -3.3% | +20.8% | 18.5 | 2.1% |
|
CSLLY
Csl Ltd
|
$61.83B | — | — | — | 0.0% |
Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding
At a glance
key data from every sectionPerformance
| 5D | 20D | 120D | MTD | YTD | |
|---|---|---|---|---|---|
| PGEN | -8.6% | +14.0% | +90.0% | -8.8% | +86.8% |
| SPY | +1.2% | +1.9% | +9.9% | +2.1% | +14.2% |
| vs SPY | -9.7% | +12.1% | +80.2% | -10.9% | +72.7% |